延迟第三剂日本无铝甲型肝炎疫苗Aimmugen可在成人中引发有效的甲型肝炎免疫应答
研究纳入29名成人旅行者,在完成前两剂Aimmugen后3-14年接种第三剂,抗甲肝病毒抗体滴度≥10 mIU/mL的血清保护率从接种前96.6%(28/29)升至接种后28-42天100%(29/29),几何平均浓度从105升至4,013 mIU/mL。结果表明延迟第三剂仍能引发有效免疫应答。
要点
- 前两剂后延迟3-14年接种第三剂Aimmugen,血清保护率从96.6%升至100%。
- 抗体几何平均浓度从105 mIU/mL升至4,013 mIU/mL。
- 延迟第三剂仍可在两剂基础免疫后引发有效免疫应答。
核心结论
- 延迟第三剂Aimmugen在两剂基础免疫后仍能引发有效的甲型肝炎免疫应答。
研究设计与样本
- 研究纳入29名成人旅行者(14男15女,平均年龄36.2±8.1岁),在第一剂后超过24周接种第三剂Aimmugen,前两剂与第三剂间隔3-14年。
主要发现
- 血清保护率(抗甲肝病毒抗体滴度≥10 mIU/mL)在接种前为96.6%(28/29),接种后28-42天升至100%(29/29)。
- 抗体几何平均浓度从105 mIU/mL升至4,013 mIU/mL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inactivated aluminum-adsorbed hepatitis A vaccines such as Havrix, Vaqta, and Avaxim are commonly used worldwide. These vaccines are typically administered in a two-dose series (at 0 and 6-12 months). However, a lyophilized inactivated aluminum-free hepatitis A vaccine, Aimmugen, which is approved in Japan, is typically administered in a three-dose series (at 0, 2-4, and 24 weeks). Hence, individuals visiting endemic hepatitis A areas receive the primary two doses of Aimmugen before traveling and the third booster dose much later. It is currently uncertain whether boosting with a delayed third dose of Aimmugen is effective, or whether a new vaccination schedule should instead be initiated. Therefore, we investigated the anti-hepatitis-A viral immune response of adult travelers who received the third dose of Aimmugen more than 24 weeks after the first dose. Participants were vaccinated with the third dose of Aimmugen more than 2 years after the first two doses. Antibody titers were measured at Day 0 (prevaccination) and at 28-42 days after the third dose of Aimmugen. Twenty-nine adult participants were enrolled in the study (14 men and 15 women; mean age ± standard deviation age, 36.2 ± 8.1 years). The interval between the first two doses and the third dose was 3-14 years. The seroprotection rate (i.e., the percentage of participants with anti-hepatitis A virus antibody titers ≥ 10 mIU/mL) was 96.6 % (28/29) at Day 0 and increased to 100 % (29/29) at Days 28-42. Geometric mean concentration increased from 105 to 4,013 mIU/mL. We demonstrated that delaying the third dose of Aimmugen still elicited effective immune responses after priming with two doses of the vaccine. Trial registration: UMIN Clinical Trials Registry (UMIN-CTR): MIN000013624. Registered 03 April 2014. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015906.
引用
- Fukushima S, Kiyohara T, Nakano T, et al. Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults. Vaccine. 2023. PMID: 37353455. doi:10.1016/j.vaccine.2023.06.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。